Merck Sharp & Dohme Corp: V591

Merck Sharp & Dohme Corp: V591

Vaccine Type: Replicating Viral Vector

This vaccine is no longer progressing. Further Details

About Trial Phases

Phase 1: 1 Trial

NCT04498247
Austria, Belgium, United States of America

Phase 2: 1 Trial

NCT04498247
Austria, Belgium, United States of America

Phase 3: 0 Trials

There are no trials for this phase.

Approvals

This vaccine is not yet approved.

Registered Trials

NCT04498247
Phase 1/2
Austria, Belgium, United States of America
Total Enrollment: 260
Official Trial Registration:
- NCT04498247(Opens in new tab/window)

© 2021 McGill COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

The information provided on this site is for informational purposes only and should not be considered to be medical advice or an indication of an endorsement. All information is based on publicly available data.

Site Credits Website Feedback Form